首页 > 产品中心 > 试剂盒 > ADA检测试剂盒

Vunakizumab ELISA Kit (KPTX263)

价格:
规格:
数量:
  • 概述

  • 图片

  • 参考文献

概述
货号KPTX263
品牌ProteoGenix
描述
Vunakizumab ELISA Kit (KPTX263) — Quantitative colorimetric ELISA. for Vunakizumab. Sample: Plasma, Serum. Range: 0.31-5 μg/mL.
Highlights
  • High Sensitivity — Reliable quantification at low concentrations.
  • Ready-to-Use — Pre-coated plates for streamlined workflow.
样本类型Plasma, Serum
检测范围0.31-5 μg/mL
保存溶液 The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

检测方法Colorimetric
实验类型Quantitative
回收率80-120%
运输2-8 ℃
规格Vunakizumab
别名SHR-1314, CAS: 1792181-33-9
背景Vunakizumab is a recombinant humanized IgGκ monoclonal antibody binds to and neutralises the proinflammatory cytokine interleukin-17A (IL-17A). It was discovered and developed by Jiangsu Hengrui Medicine (China) with the developmental name SHR-1314, for the treatment of autoimmune diseases such as psoriasis, psoriatic arthritis, ankylosing spondylitis, multiple sclerosis and inflammatory arthritis. Atridia Pty. Ltd., which is now a part of Jiangsu Hengrui Medicine, start a phase-I clinical trial in psoriasis (in volunteers) in Australia in August 2016. Atridia completed the phase-I trial in July 2017. A phase-I/II study, which is started from December 2017, is ongoing to assess the safety, tolerability, and pharmacokinetics of SHR-1314 with expanded dose finding in subjects with moderate-to-severe plaque psoriasis.
NoteFor Research Use Only.
图片
参考文献
公式
质量 (g) = 浓度 (mol/L) × 体积 (L) × 分子量 (g/mol)
填写 质量、浓度、体积中的任意 2 项 + 分子量,自动计算未知值。
质量
=
浓度
×
体积
分子量 *
g/mol
公式
C₁ × V₁ = C₂ × V₂
填写 4 项中的任意 3 项,自动计算未知值。
母液
C₁ (起始浓度)
×
V₁ (起始体积)
=
工作液
C₂ (终浓度)
×
V₂ (终体积)

相关产品推荐